Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of “Buy” by Analysts

Delcath Systems, Inc. (NASDAQ:DCTH) has earned an average recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $19.83.

Several equities research analysts have recently commented on the company. HC Wainwright lifted their target price on Delcath Systems from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Stephens began coverage on shares of Delcath Systems in a research report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price on the stock. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. Finally, Craig Hallum started coverage on shares of Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 price objective on the stock.

Delcath Systems Stock Down 4.2 %

Shares of NASDAQ:DCTH opened at $7.91 on Wednesday. The firm has a market cap of $219.82 million, a P/E ratio of -2.98 and a beta of 0.64. Delcath Systems has a 12 month low of $2.25 and a 12 month high of $9.18. The company’s 50-day moving average price is $6.93 and its two-hundred day moving average price is $5.28.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $3.70 million. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. As a group, equities analysts predict that Delcath Systems will post -1.31 earnings per share for the current fiscal year.

Institutional Trading of Delcath Systems

Hedge funds have recently added to or reduced their stakes in the business. AIGH Capital Management LLC bought a new stake in shares of Delcath Systems in the fourth quarter worth about $4,918,000. Vivo Capital LLC grew its position in shares of Delcath Systems by 94.9% in the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock valued at $7,950,000 after purchasing an additional 811,555 shares during the period. Worth Venture Partners LLC bought a new stake in Delcath Systems during the 4th quarter worth approximately $1,224,000. ADAR1 Capital Management LLC acquired a new stake in Delcath Systems during the 4th quarter worth approximately $962,000. Finally, BVF Inc. IL lifted its stake in Delcath Systems by 23.1% in the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after buying an additional 225,918 shares in the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.